NGNE Neurogene Inc. Insider Trading

10% owner Samsara BioCapital bought 48,770 shares (48.8K) totaling $1,259,622.58 ($1.3M) at blended avg $25.83; part of cluster buy pattern

Samsara BioCapital GP, LLC executed 4 separate purchases totaling 48,770 shares for $1,259,622.58 on 2024-11-26, increasing its holding to 1,717,127 shares post-transaction. The filing coincides with a cluster buy pattern: 2 other insiders also purchased within the past 14 days. Stock has declined -63.9% from its 52-week high of $71.53 and -43.8% over the past 30 days, trading near the blended purchase price of $25.83. The company remains unprofitable (net income $-20,217,000.00 for latest quarter; negative net income for full fiscal year) with zero latest-quarter revenue, elevating execution risk. Samsara's cross-ticker track record shows 75.00% win rate and +46.7% average 90-day return on prior buys, but this metric spans multiple tickers and does not indicate same-ticker conviction or timing accuracy at Neurogene.

CEO Rachel McMinn buys 47,500 shares of NGNE at $20.40 amid 68.8% decline from 52-week high; stock down 53.9% in 30 days.

Rachel McMinn, CEO of Neurogene Inc., purchased 47,500 shares at $20.40 on 2024-11-22, bringing her total holdings to 1,297,859 shares. This transaction occurs against a backdrop of significant recent weakness: the stock is trading at $22.32, down 68.8% from its 52-week high of $71.53 and down 53.9% over the past 30 days. The company is unprofitable, with net income of $-20,217,000.00 for the most recent full fiscal year and $0.00 revenue in the latest quarter. The CEO's decision to acquire 47,500 additional shares during a period of severe stock underperformance warrants attention to whether this reflects confidence in an operational turnaround or whether it reflects other considerations not visible in public filings.

CFO Christine Mikail bought 24,000 shares of NGNE at $20.48 ($491.4K); stock down -68.8% from 52-week high, company unprofitable with $-20.2M net income.

Cvijic Christine Mikail, President and CFO, purchased 24,000 shares at $20.48 on 2024-11-22, increasing her holdings by 45.4% to 76.8K shares. This buy occurred in a difficult context: the stock trades at $22.32, down -68.8% from its 52-week high of $71.53 and -53.9% over the past 30 days. Neurogene reported $0.00 revenue in the latest quarter and a net loss of $-20.2M over its most recent full fiscal year. An insider equity purchase of this size by the CFO during a period of steep price decline and unprofitability is material and merits scrutiny of the company's forward guidance and burn rate expectations.